Influence of metoprolol on systolic and diastolic function in children with heart failure

F R Ghader1, Z A Abaskhanian

  • 1Department of Pediatric Cardiology, Booali Sina Hospital, Mazandaran University of Medical Sciences, Pasdaran Boulevard, P.O. Box 48158-38477, Sari, Iran.

Insights

Metoprolol improved cardiac systolic and diastolic function in pediatric heart failure patients with structural heart defects. This beta-blocker is recommended for children with heart failure inadequately controlled by standard therapies.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Pharmacology

Background:

  • Heart failure in children often results from structural heart defects like VSD, PDA, AI, and MR.
  • Left ventricle volume overload is a common cause of pediatric heart failure.

Purpose of the Study:

  • To evaluate the efficacy of metoprolol in improving cardiac function in children with heart failure.
  • To assess the effects of metoprolol on systolic and diastolic function in pediatric patients with structural heart disease.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 30 pediatric patients.
  • Patients received either metoprolol (1 mg/kg/day) or placebo for 3 months.
  • Echocardiography was used to measure cardiac indices of systolic and diastolic function at baseline and monthly.

Main Results:

  • Metoprolol significantly improved cardiac index (CI), myocardial performance index (MPI), and dv/dt(dt) within the first month.
  • Left ventricular ejection fraction (LVEF) and E-point septal separation (EPSS) showed significant improvement by the second month.
  • E wave and E/A ratio demonstrated significant changes by the third month, indicating diastolic function enhancement.

Conclusions:

  • Metoprolol effectively improves both systolic and diastolic cardiac function in children suffering from heart failure due to structural defects.
  • Metoprolol is a recommended therapeutic option for pediatric heart failure patients with inadequately controlled conditions despite standard treatments.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...